Gilead Sciences bought nearly 950,000 more shares of antiviral-therapeutics developer Assembly as part of an amended ...

Gilead stock rated buy for thriving HIV biz, promising oncology pipeline, and long-term growth potential despite volatility.

Gilead Sciences Inc (GILD) stock saw a decline, ending the day at $94.11 which represents a decrease of $-0.30 or -0.32% from the prior close of $94.41. The stock opened at $93.43 and touched a low of ...

Nvidia has dominated the AI narrative in the stock market, captivating investors and the media after soaring 2,190% over the ...

Biotech giant Gilead Sciences, Inc. GILD has put up a steady performance in 2024 amid a volatile market. Its shares have ...

Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $93.95 which represents a slight increase of $0.55 or 0.59% from the prior close of $93.4. The stock opened at $93 and touched ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Value stocks -- a market segment that includes high-yield stocks -- outperformed growth stocks in 2022. That's a recent rarity, as for more than a decade, the performance record favored growth ...

Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical company, discovers, develops and commercializes medicines to address ...

Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $1,075.53 today based on a ...

Investors are bullish on Gilead as the stock surges on successful launches and strong financial health, offering potential ...

For years, Gilead Sciences was dead money for shareholders. Shares of the drugmaker, with a market capitalization of just ...